We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/9/2019 13:40 | Thanks ,outsizec.com. Thought -afterwards, doh - that that was probably your line of thinking. All fine for now. | dogwalker | |
12/9/2019 12:11 | Hi Dogwalker, In smaller stocks I tend to "round up" rather than follow 'exact' prices. £1.875 / £1.90 - we're on the same page ;-) When I say "a definite break below 190" I mean a close of 180 (or below), for more than 1 day (to rule out a downward 'spike' that immediately recovers), or a close of week price at that level. | outsizeclothes.com | |
11/9/2019 16:39 | What date does the £1.90 'resistance level' relate from , outsizeclthes.com? I ask because I'm using £1.8725 from 28th June as the same thing i.e we're at it now. | dogwalker | |
11/9/2019 15:37 | Conversely, if we can hold onto £1.90 (+) the upside resistance becomes 240, then 270, then 3.20 | outsizeclothes.com | |
11/9/2019 15:33 | A definite break under £1.90 here is very bad news chart-wise. Having, at under 190, gone through a "triple-bottom", the first area of support isn't until the £1 'resistance level' of July last year, and below that serious support does not kick in until late March's 80p. If it closes at under 190p end of week, £1 inside 2 months is the chart's downside target. | outsizeclothes.com | |
10/9/2019 21:21 | Still tanking on high volume ffs | bigspuds | |
10/9/2019 10:23 | Manjana on the stroke trial but the previous results were mediocre and only helped the share price to decline to 48p. On the other hand, the results from the RP trial were excellent. Announcing the update to the latest RP trials to a major US ophthalmology meeting suggests the trial must be going well. Why would you want to embarrass yourself in front of your peers? Exosomes as a delivery vehicle in for nothing. And "We remain in discussions with other commercial third parties regarding potential collaboration and/or out-licensing deals across our programmes." | dickbush | |
10/9/2019 09:09 | Schumacher in for stem cell treatment too: | philh75 | |
10/9/2019 08:55 | But the RENE science is just as exciting! | bonzo | |
10/9/2019 08:09 | Not such good news for rene though, ie, not connected to rene product! | rayrac | |
10/9/2019 03:13 | That is truly wonderful,Making the blind see again. | elmfield | |
10/9/2019 02:38 | Great news for James O'Brien! Very happy to see that he has benefitted from science that only a few years ago would seem to be a dream. Hope his recovery improves and improves! Exciting for RENE to be involved in such science. | lauders | |
09/9/2019 09:28 | Not expecting much from the agm..unless we also have a decent rns at about the same time. | rayrac | |
07/9/2019 12:13 | AGM next week. | dickbush | |
06/9/2019 18:09 | Not looking good..needs some results/news. | rayrac | |
04/9/2019 06:31 | Interesting and great news for the children it will help! Retinal dystrophy is not a single condition, but comprises a wide range of disorders such as Retinitis Pigmentosa. Most retinal dystrophies are genetic, caused by a mistake in a patient's genes. Today’s announcement provides treatment to those with a specific faulty gene, RPE65, which blocks the messages that make proteins in the eye which are essential for normal vision. It is estimated there are currently up to 100 patients, including children and adults, living with the retinal dystrophy who will be eligible for the new treatment. Around 3 to 5 babies are expected to be born every year suffering with the condition. In order to undergo the treatment, patients will be tested for the faulty gene and if they test positive they will be eligible. NHS England reached a deal with manufacturer Novartis to fund the drug, which costs £613,410 per patient at full price. | lauders | |
02/9/2019 09:20 | And an even stranger start to the week...no feeds! | rayrac | |
30/8/2019 19:46 | Oh well, a strange end to the week? Don’t ask me how to interpret it. | rayrac | |
29/8/2019 22:53 | My guess is the same as yours, Rayrac. I've seen this many times but I still don't know what the signals indicate. Fingers crossed. | dickbush | |
29/8/2019 21:23 | The shares finished at 245p on my SIPP account | volsung | |
29/8/2019 20:49 | 3 shares a signal of some sort? Very strange, not to keen on tomorrow’s opening. | rayrac | |
29/8/2019 18:14 | Someone has sausage fingers... | masingi | |
29/8/2019 16:57 | Let's hope so; and for the better. Hope someone hasn't offloaded a shedload of shares into the rise in the share price today. | investordave | |
29/8/2019 16:51 | Ignore the close. Tomorrow's trading will sort it out. | dickbush |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions